Healthcare Mar 01, 2022 08:18 AM (GMT+8) · EqualOcean
Cinda biopharmaceutical group and Baoyuan pharmaceutical jointly announced that taletretinib (Cinda R & D Code: ibi-344, Baoyuan R & D Code: AB-106) has been included in the list of breakthrough therapeutic drugs by the drug review center (CDE) of China National Drug Administration (nmpa), The proposed indications are patients with ros1 fusion positive non-small cell lung cancer who have not been treated with ros1 tyrosine kinase inhibitor (TKI) and who have previously received ros1 TKI.
Related companies: